

1AP5 Rec'd PCT/PTO 21 MAR 2006

10/574087 Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Norikazu Ohtake, et al.  
Int'l Appln.  
No. : PCT/JP2004/013768  
Int'l Date  
Filed : 21 September 2004 (09/21/2004)  
Serial No. : (To be assigned) Case No.: BY0031  
Filed : March 21, 2006  
For : NOVEL PIPERIDINE DERIVATIVE

Commissioner for Patents  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT 3-21-2006  
EXPRESS MAIL NO. EV660608364 US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Kathy Klutkowski  
DATE 3-21-06

**IAP5 Rec'd PCT/PTO 21 MAR 2006**

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 

Eric Thies  
Reg. No. 35,382  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904

Date: March 21, 2006

*(use as many sheets as necessary)*

Sheet

**1**

of

**1**

Application Number:

**Filing Date****First Named Inventor**

### Group Art Unit

Examiner Name

Attorney Docket Number

**COMPLETE IF KNOWN**

ec'd PCT/PTO 21 MAR 2006  
March 21, 2006 10/574087

Norikazu Ohtaku

BY0031

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/VB/			WO 2004/037257		Janssen Pharmaceutica N.V.	05/06/2004
			WO 99/24406		Schering Corporation	05/20/1999
			WO 02/099388		Merck & Co., Inc.	12/12/2002
			WO 02/076925		Eli Lilly and Company	10/03/2002
/VB/			WO 2004/069792		Janssen Pharmaceutica N.V.	08/19/2004

**Examiner  
Signature**

/Venkataraman Balasubramanian/

Date Considered

01/11/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005